Cart is empty The U.S. Food and Drug Administration has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
The U.S. Food and Drug Administration has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Leave A Comment